pharmaphorum

DECEMBER 3, 2020

Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP) inhibitor drugs.

DNA 94

DNA Genetics Research Sales 94

Roots Analysis

DECEMBER 12, 2021

DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. DNA data storage is an innovative technology that works by encoding large digital data sequences of binary form (0s and 1s) into DNA sequences (Adenine (A), Guanine (G), Cytosine (C) and Thymine (T)). DNA Storage.

DNA 52

DNA Research Engineer Marketing 52

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

BioPharma Reporter

MARCH 3, 2022

UK headquartered Touchlight has agreed a development and manufacturing pipeline agreement with Swiss company, Versameb.

Manufacturing 98

Manufacturing DNA Development Regulation 98

pharmaphorum

APRIL 13, 2022

Slick productions to maximise digital opportunities and algorithm-powered insights play a strong role in linking industry campaigns to the healthcare coal face but deeper connections can be mined by making coaching part of an organisation’s DNA. Coaching has to be part of the DNA,” he adds. “It A critical mind-shift is needed.

DNA 98

DNA Sales Development Production 98

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. to complete an in-house plasmid DNA facility in Marburg, Germany. “In In February 2023, the mRNA specialist BioNTech invested $43.8m

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

BioTech 365

SEPTEMBER 21, 2020

DUBLIN–(BUSINESS WIRE)–The “DNA Sequencing – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications.

DNA 40

DNA Marketing Genome Genomics 40

BioPharma Reporter

JANUARY 17, 2022

Andelyn Biosciences says the FDA's acceptance of its GMP plasmid DNA drug master file (DMF) enables the CDMO to vertically integrate its clientsâ manufacturing process, condensing timelines for developers to begin manufacturing to just three months.

Gene Therapy 105

Gene Therapy Development DNA Gene 105

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The company provides end-to-end contract development and manufacturing organisation (CDMO) services from the discovery to the commercialisation of drugs.

Vaccination 289

Vaccination Vaccine Gene Therapy Manufacturing 289

Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Join this free roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). Driven by the rapid pace of innovation, the market for CGTs is expected to grow from $4.4 billion in 2020 to $15.5 billion in 2025 at a rate of 28.7%

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. What can we expect from the cell & gene therapy market? Panellists will discuss the following questions: Where will the opportunities be in 2024?

Development 52

Development Gene Therapy Drugs DNA 52

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

Roots Analysis

NOVEMBER 5, 2023

Over time, extensive research in liquid biopsy market has resulted in the recognition of minimally invasive liquid biopsies as a viable technique for cancer detection. Additionally, various clinical research are required to understand the detailed mechanism that correlates blood-based biomarkers with tumor development.

Marketing 40

Marketing Genetics DNA Research 40

Delveinsight

JULY 26, 2021

However, antibiotics are the only available treatment options in the Uncomplicated Urinary Tract Infections market to cater to such a large patient pool. Some of the most commonly prescribed antibiotics in the Uncomplicated Urinary Tract Infection therapy market include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, ?-lactams,

Marketing 93

Marketing Bacteria Vaccination Vaccine 93

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. At present, most antibody tests on the market require samples to be sent to a lab for analysis.

DNA 52

DNA Antibody Research Genome 52

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. The various advantages of NGS are briefly described below: Next Generation Sequencing (NGS) Library Preparation Kits Market – Roots Analysis.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio. The financial terms of the deal were not disclosed by the companies.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

Drug Discovery World

FEBRUARY 6, 2024

From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and optimising laboratory workflows, digital technologies are having a significant impact on drug discovery and development. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

Medical Xpress

MAY 1, 2023

A decade after scientists developed the ability to edit DNA using the CRISPR sequence, the first drugs using the technique are approaching the market, with the potential to transform the lives of people with certain genetic illnesses. But questions of ethics, access, and pricing remain.

DNA 75

DNA Genetics Scientist Marketing 75

Roots Analysis

FEBRUARY 27, 2024

Over the last few decades, various viral vector manufacturing have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option.

Manufacturing 52

Manufacturing Gene Therapy Gene DNA 52

Pharmaceutical Technology

MAY 24, 2023

The investigational DNA medicine candidate INO-3107 has been designed for eliciting a targeted T cell response against HPV[human papillomavirus]-6 and HPV-11, the types of HPV that cause RRP and other related diseases.

Drugs 130

Drugs DNA Medicine Regulation 130

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JUNE 15, 2023

Onivyde works by blocking an enzyme called topoisomerase I, which is involved in copying cell DNA. It has already been approved in combination with fluorouracil and leucovorin to treat patients with mPDAC after disease progression following gemcitabine-based therapy in major markets, including the EU, Asia and the US.

DNA 130

DNA Regulation Trials Drugs 130

BioPharma Reporter

SEPTEMBER 19, 2023

The UK startup Broken String Biosciences has raised a $15 million Series A round to fund the development of a DNA sequencing platform that maps off-target DNA breaks resulting from genome editing technology.

Genome 52

Genome Genomics DNA Development 52

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. Personalised medicines will also be developed at the centre.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Production 100

Production DNA Clinical Trials Clinical Trials 100

Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 52

Production Reagent DNA Drugs 52

XTalks

NOVEMBER 28, 2023

Kesin Pharma is headquartered in New York and focuses on the development, manufacturing and commercialization of generic and innovative products in liquid and semi-solid dosage forms. Alternative Products in the Market In addition to the oral suspension Likmez, there are alternative FDA-approved treatments for similar indications.

FDA Approval 103

FDA Approval Bacteria DNA Drugs 103

Pharmaceutical Technology

DECEMBER 14, 2022

Antibiotics are the go-to treatment for bacterial infections in developed countries, such as Strep A. Bacteria naturally develop resistance to antibiotics over time, through genetic mutation, horizontal gene transfer between bacteria, or because of selective pressure. The antibiotic conundrum. Phages are lytic or temperate.

Bacteria 130

Bacteria DNA Clinical Trials Clinical Trials 130

BioPharma Reporter

JULY 13, 2023

EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing.

DNA 52

DNA Medicine Development Regulation 52

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. billion) mark.

Marketing 52

Marketing Business Development Genome Genomics 52

XTalks

JUNE 16, 2023

XTALKS WEBINAR: Point-of-Care Diagnostics: Best Practices for Bringing Novel Solutions to Market Live and On-Demand: Thursday, July 13, 2023, at 1pm EDT (10am PDT) Register for this free webinar to gain insights from industry leaders on best practices for commercializing point-of-care diagnostic innovations. billion in 2022 to $15.91

FDA Approval 97

FDA Approval Genome Genomics DNA 97